# Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer

> **NCT02688608** · PHASE2 · COMPLETED · sponsor: **Saad A Khan** · enrollment: 6 (actual)

## Conditions studied

- Anaplastic Thyroid Cancer

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02688608
- **Lead sponsor:** Saad A Khan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2020-10
- **Final completion:** 2021-10
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2022-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02688608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02688608, "Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02688608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*